Research programme: small molecule gene expression modulators - Gilead/ PTC Therapeutics

Drug Profile

Research programme: small molecule gene expression modulators - Gilead/ PTC Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Developer Gilead Sciences; PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Low HDL cholesterol

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in USA (PO)
  • 15 Mar 2010 Preclinical development is ongoing
  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top